d
e
ri s
o
u t h
r   a
e
Dimethyl fumarate Neuraxpharm 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
g
n
o  l o
Decision 
Information 
Issued2 / 
affected3  
amended 
on 
c t  n
Notification1 
issued on 
u
12/04/2023 
PL 
19/12/2022 
SmPC and PL 
N/0008 
IB/0007 
d
o
r
a l  p
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
d i c i n
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
e
M
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
d
e
ri s
o
u t h
IB/0006/G 
This was an application for a group of variations. 
07/12/2022 
12/01/2023 
SmPC and PL 
C.I.11.a - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0005/G 
This was an application for a group of variations. 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
d
o
r
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
a l  p
d i c i n
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
site 
e
M
IA/0004/G 
This was an application for a group of variations. 
27/07/2022 
n/a 
r   a
e
g
n
o  l o
n/a 
27/09/2022 
c t  n
u
changes to an approved test procedure 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
20/07/2022 
c t  n
u
B.II.e.5.a.2 - Change in pack size of the finished 
20/07/2022 
IB/0002 
IAIN/0001/G 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
a l  p
This was an application for a group of variations. 
d
o
r
d i c i n
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
B.II.e.5.a.1 - Change in pack size of the finished 
site 
e
M
site 
d
e
ri s
o
u t h
r   a
e
g
n
o  l o
n/a 
12/01/2023 
SmPC, 
Labelling and 
PL 
13/06/2022 
12/01/2023 
SmPC, Annex 
II, Labelling 
and PL 
product - Change in the number of units (e.g. 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
d
o
r
a l  p
site 
e
M
d i c i n
d
e
ri s
o
u t h
r   a
e
g
n
o  l o
c t  n
u
Page 4/4 
 
 
 
 
 
 
 
